CoreLab Partners, Inc., announced the opening of an office in Tokyo, Japan under the wholly owned subsidiary of CoreLab Partners Japan, K.K.
“We are pleased to announce the creation of our new subsidiary in Asia corresponding with the opening of an office in central Tokyo” said CoreLab Partners’ President and Chief Executive Officer, Dr. Mike Woehler. “This expanded presence is a natural extension of our geographic reach and global strategy to serve our growing base of multinational biopharma companies operating in the region and will complement our operational capability which was established in Shanghai, China over a decade ago” added Woehler.
CoreLab Partners currently has a business alliance in Japan with Suzuken Co. Ltd. which markets its cardiac safety services; this new presence is designed to further establish the global brand in the Pacific Rim and expand their full line of imaging sciences capabilities in Southeast Asia. “CoreLabs has been present in the region since 1999 and has conducted hundreds of drug development studies in both cardiac safety and imaging for a variety of sponsor partners. The addition of a local Regional Director and Business Development professional will allow CoreLab Partners to better service our client base by nurturing current relationships and opening up new markets for our full line of cardiac safety and imaging services” said Kevin Duffy, Vice President, Global Business Development.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.